New antibody takes on Hard-to-Treat cancers

NCT ID NCT04243499

Ongoing Disease control Sponsor: ImCheck Therapeutics, an Ipsen company Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 12, 2026 · Updated 5 times

Summary

This early-stage trial tests a new drug called ICT01, a lab-made antibody, in 292 people with advanced cancers that have not responded to standard treatments. The drug is given alone or with another cancer drug (Keytruda). The main goals are to check safety and see if the drug can control tumor growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ICT01 (a monoclonal antibody targeting BTN3A)
What this could lead to: If successful, this could point toward a new treatment option for advanced cancers that have stopped responding to standard therapies.
What could go wrong: This is an early Phase 1/2 trial, so the main goal is safety, not proof of effectiveness. It may not work for many patients, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOPOIETIC/LYMPHOID CANCER SOLID TUMOR, ADULT

Contacts and locations

Locations

Banner MD Anderson Cancer Center

Gilbert, Arizona, 85234, United States
CHU Lyon

Lyon, France
CHU Nantes

Nantes, 44093, France
CHU Poitiers

Poitiers, 86000, France
Centre Antoine Lacassagne

Nice, 06189, France
Centre Hospitalier Lyon Sud

Lyon, 69310, France
Centre Lyon Berard

Lyon, France
City of Hope Comprehensive Cancer Center

Duarte, California, 91010, United States
Gustave Roussy

Paris, France
H. Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, 33612, United States
Haut Leveque

Bordeaux, 33600, France
Hospital Universitario HM Sanchinarro

Madrid, 28050, Spain
Institut Bergonie

Bordeaux, 33000, France
Institut Curie

Paris, 75248, France
Institut Jules Bordet

Brussels, Belgium
Institut Paoli-Calmettes

Marseille, France
Institute of Cancer Research

London, United Kingdom
Montefiore Medical Center

The Bronx, New York, 10467, United States
NHS Greater Glasgow and Clyde, Beatson West of Scotland Cancer Centre

Glasgow, United Kingdom
Pitie-Salpetriere

Paris, 75013, France
START Barcelone HM Nou Delfos

Barcelona, 08023, Spain
START Madrid-FJD, Hospital Fundación Jiménez Díaz

Madrid, 28040, Spain
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
US Oncology Research

Irving, Texas, 75063, United States
University Carl Gustav Carus Clinical Trial Unit

Dresden, Germany
University of Washington

Seattle, Washington, 98133, United States
Vall d'Hebron Instiute of Oncology

Barcelona, Spain
Yale Cancer Center

New Haven, Connecticut, 06511, United States
universitatklinikum Wurburg

Würzburg, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.